349 related articles for article (PubMed ID: 24590894)
1. Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
Chen EP; Markosyan N; Connolly E; Lawson JA; Li X; Grant GR; Grosser T; FitzGerald GA; Smyth EM
Carcinogenesis; 2014 Aug; 35(8):1788-97. PubMed ID: 24590894
[TBL] [Abstract][Full Text] [Related]
2. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
[TBL] [Abstract][Full Text] [Related]
3. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
Markosyan N; Chen EP; Ndong VN; Yao Y; Sterner CJ; Chodosh LA; Lawson JA; Fitzgerald GA; Smyth EM
Carcinogenesis; 2011 Oct; 32(10):1441-9. PubMed ID: 21771729
[TBL] [Abstract][Full Text] [Related]
4. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
5. CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
Racioppi L; Nelson ER; Huang W; Mukherjee D; Lawrence SA; Lento W; Masci AM; Jiao Y; Park S; York B; Liu Y; Baek AE; Drewry DH; Zuercher WJ; Bertani FR; Businaro L; Geradts J; Hall A; Means AR; Chao N; Chang CY; McDonnell DP
Nat Commun; 2019 Jun; 10(1):2450. PubMed ID: 31164648
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation.
Ryu MS; Woo MY; Kwon D; Hong AE; Song KY; Park S; Lim IK
Exp Cell Res; 2014 Oct; 327(2):209-21. PubMed ID: 25088256
[TBL] [Abstract][Full Text] [Related]
7. Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
Barakat DJ; Suresh R; Barberi T; Pienta KJ; Simons BW; Friedman AD
PLoS One; 2018; 13(1):e0191188. PubMed ID: 29324844
[TBL] [Abstract][Full Text] [Related]
8. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.
Schmidt K; Zilio S; Schmollinger JC; Bronte V; Blankenstein T; Willimsky G
Blood; 2013 Mar; 121(10):1740-8. PubMed ID: 23305737
[TBL] [Abstract][Full Text] [Related]
9. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
Aharinejad S; Paulus P; Sioud M; Hofmann M; Zins K; Schäfer R; Stanley ER; Abraham D
Cancer Res; 2004 Aug; 64(15):5378-84. PubMed ID: 15289345
[TBL] [Abstract][Full Text] [Related]
10. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
[TBL] [Abstract][Full Text] [Related]
11. Premetastatic soil and prevention of breast cancer brain metastasis.
Liu Y; Kosaka A; Ikeura M; Kohanbash G; Fellows-Mayle W; Snyder LA; Okada H
Neuro Oncol; 2013 Jul; 15(7):891-903. PubMed ID: 23595625
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
13. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
14. Myeloid Differentiation Factor 88 Signaling in Bone Marrow-Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment.
Maeda Y; Echizen K; Oshima H; Yu L; Sakulsak N; Hirose O; Yamada Y; Taniguchi T; Jenkins BJ; Saya H; Oshima M
Cancer Prev Res (Phila); 2016 Mar; 9(3):253-63. PubMed ID: 26888865
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
16. Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization.
Barberi T; Martin A; Suresh R; Barakat DJ; Harris-Bookman S; Drake CG; Lim M; Friedman AD
Cancer Immunol Immunother; 2018 Oct; 67(10):1491-1503. PubMed ID: 30030559
[TBL] [Abstract][Full Text] [Related]
17. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells.
Zhang Y; Lv D; Kim HJ; Kurt RA; Bu W; Li Y; Ma X
Cell Res; 2013 Mar; 23(3):394-408. PubMed ID: 23266888
[TBL] [Abstract][Full Text] [Related]
18. Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
Mamlouk S; Kalucka J; Singh RP; Franke K; Muschter A; Langer A; Jakob C; Gassmann M; Baretton GB; Wielockx B
Int J Cancer; 2014 Feb; 134(4):849-58. PubMed ID: 23913502
[TBL] [Abstract][Full Text] [Related]
19. HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.
Benight NM; Wagh PK; Zinser GM; Peace BE; Stuart WD; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
Oncotarget; 2015 Jul; 6(19):17445-61. PubMed ID: 25938541
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H
Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
